There are currently 52 clinical trials in Athens, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including University Cancer and Blood Center LLC, University of Georgia, University Cancer & Blood Center, LLC and Northeast Georgia Cancer Care, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452
Recruiting
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
Gender:
All
Ages:
12 years and above
Trial Updated:
06/13/2024
Locations: Summit Clinical Research, LLC, Athens, Georgia
Conditions: Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants wil... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Summit Clinical Research, LLC, Athens, Georgia
Conditions: Diabetic Gastroparesis
Register for Updates
Steps Towards Osteoarthritis Prevention
NCT06193343
Recruiting
Optimal knee joint loading, which refers to the forces acting on the knee caused by daily activities such as daily steps, plays an essential role in maintaining knee articular cartilage health and reducing the risk of osteoarthritis (OA). After anterior cruciate ligament reconstruction (ACLR), individuals take fewer daily steps as compared to uninjured controls resulting in insufficient knee joint loading to joint tissues, but it is unclear how changes in daily steps impact knee joint cartilage... Read More
Gender:
All
Ages:
Between 16 years and 40 years
Trial Updated:
06/11/2024
Locations: University of Georgia, Athens, Georgia
Conditions: Anterior Cruciate Ligament Injuries
Register for Updates
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
Recruiting
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of ev... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University Cancer & Blood Center, LLC, Athens, Georgia
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Northside Hospital,125 King Avenue, Athens, Georgia
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Research Site, Athens, Georgia
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: 89bio Clinical Study Site, Athens, Georgia
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: University Cancer and Blood Center LLC, Athens, Georgia
Conditions: Stage III Colon Cancer
Register for Updates
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
All
Ages:
All
Trial Updated:
06/05/2024
Locations: University Cancer & Blood Center, LLC; Research, Athens, Georgia
Conditions: Solid Tumors
Register for Updates
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585
Recruiting
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/04/2024
Locations: Research Site, Athens, Georgia
Conditions: Breast Cancer
Register for Updates
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT05249101
Recruiting
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2024
Locations: University Cancer and Blood Center, Athens, Georgia
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793
Recruiting
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: University Cancer and Blood Center, Athens, Georgia
Conditions: Liposarcoma, Dedifferentiated
Register for Updates